Actively Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Led by Amgen · Updated on 2026-03-27
380
Participants Needed
19
Research Sites
278 weeks
Total Duration
On this page
Sponsors
A
Amgen
Lead Sponsor
A
Asher Biotherapeutics, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
CONDITIONS
Official Title
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant has provided informed consent before starting any study procedures
- Age 18 years or older (or legal age in country if older) at consent
- Histologically or cytologically confirmed extensive stage small cell lung cancer that progressed or recurred after at least one prior anti-cancer therapy
- At least one measurable lesion per RECIST 1.1 within 21 days before screening, not previously irradiated
- Adequate organ function including hematological, coagulation, cardiac, pulmonary, kidney, and liver function
- Able to provide a fresh tumor biopsy at screening or archival tissue collected after last anticancer therapy if fresh biopsy is unsafe or not feasible
You will not qualify if you...
- Symptomatic central nervous system metastases
- Prior treatment with any DLL3-directed therapy including tarlatamab
- Previous interleukin (IL)-2, IL-7, or IL-15 targeted therapy
- Baseline need for supplemental oxygen at rest
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
Actively Recruiting
2
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Actively Recruiting
3
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
4
Emory University
Atlanta, Georgia, United States, 30322
Actively Recruiting
5
Norton Cancer Institute - Downtown
Louisville, Kentucky, United States, 40202-1703
Actively Recruiting
6
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
7
Memorial Sloan Kettering Cancer Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
8
Siteman Cancer Center
St Louis, Missouri, United States, 63110
Actively Recruiting
9
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
10
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
Actively Recruiting
11
Avera Cancer Institute
Sioux Falls, South Dakota, United States, 57105
Actively Recruiting
12
Baptist Cancer Center
Memphis, Tennessee, United States, 38120
Actively Recruiting
13
Swedish Cancer Institute Medical Oncology
Seattle, Washington, United States, 98109
Actively Recruiting
14
Chungbuk National University Hospital
Cheongju Chungbuk, South Korea, 28644
Actively Recruiting
15
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
16
Severance Hospital Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
17
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, Turkey (Türkiye), 01370
Actively Recruiting
18
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, Turkey (Türkiye), 06230
Actively Recruiting
19
Ankara Bilkent Sehir Hastanesi
Ankara, Turkey (Türkiye), 06800
Actively Recruiting
Research Team
A
Amgen Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here